Influence of Biopsy Technique on Moleculargenetic Tumor Characterisation in NSCLC (PROFILER)
A Prospective, Randomized, Single Blinded Multicentre Trial to Evaluate Molecular Genetic Characterisation of Primary Diagnosed or Relapsed Non Small Cell Lung Cancer by Single or Combination of Diagnostic Procedures
Sponsor: AstraZeneca
This NA trial investigates Carcinoma, Non-Small-Cell Lung and Pathology, Molecular and is currently ongoing. AstraZeneca leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
May 2024 — Jul 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Sep 2022 — May 2024 [monthly]
Recruiting NA
Status: Unknown Status → Recruiting
▶ Show 3 earlier versions
-
Jan 2022 — Sep 2022 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2021 — Jan 2022 [monthly]
Recruiting NA
-
Jul 2019 — Jan 2021 [monthly]
Recruiting NA
First recorded
Dec 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- University Hospital Tuebingen
For direct contact, visit the study record on ClinicalTrials.gov .